Terminated PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT00040404

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease

Sponsor: Cephalon

Conditions Parkinson Disease

Interventions CEP-1347 10mg CEP-1347 50mg CEP1347 25mg Placebo Comparator

Updated 9 times since 2017 Last updated: May 8, 2012 Started: Mar 31, 2002 Primary completion: Aug 31, 2005 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Unlikely to provide evidence of significant effect

Other terminated trials from Cephalon

See all terminations from Cephalon

Other Parkinson Disease trials with similar outcome

Browse all Parkinson Disease trials

This PHASE2/PHASE3 trial investigates Parkinson Disease and is currently terminated or withdrawn. Cephalon leads this study, which shows 9 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Jan 2022 — Apr 2022 [monthly]

Terminated PHASE2_PHASE3

▶ Show 4 earlier versions

Jan 2021 — Jan 2022 [monthly]

Terminated PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2_PHASE3

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cephalon
H. Lundbeck A/S
The Parkinson Study Group

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Augusta, United States , Baltimore, United States , Boston, United States , Calgary, Canada , Charlottesville, United States , Chicago, United States , Cincinnati, United States , Cleveland, United States , Denver, United States and 49 more locations